DC-CIK as a widely applicable cancer immunotherapy

References

• Christofi T, Baritaki S, Falzone L, et al. Current perspectives in cancer immunotherapy. Cancers (Basel). 2019 Sep 30;11:10.
   Web of Science ®Google Scholar
• Marshall HT, Djamgoz MBA. Immuno-oncology: emerging targets and combination therapies. Front Oncol. 2018;8:315.
   PubMed Web of Science ®Google Scholar
• Boyiadzis MM, Dhodapkar MV, Brentjens RJ, et al. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018 Dec 4;6(1):137.
   PubMed Web of Science ®Google Scholar
• Kosti P, Maher J, Arnold JN. Perspectives on chimeric antigen receptor T-cell immunotherapy for solid tumors. Front Immunol. 2018;9:1104.
   PubMed Web of Science ®Google Scholar
• Sarnaik A, Khushalani NI, Chesney JA. et al. Safety and efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies -independent review committee data update. SITC Annual Meeting 2019. National harbor. USA. abstract P865.
   Google Scholar
• Higano CS, Armstrong AJ, Sartor AO, et al. Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. Cancer. 2019 Dec 1;125(23):4172–4180.
   PubMed Web of Science ®Google Scholar
• Chen R, Deng X, Wu H, et al. Combined immunotherapy with dendritic cells and cytokine-induced killer cells for malignant tumors: a systematic review and meta-analysis. Int Immunopharmacol. 2014 Oct;22(2):451–464.
   PubMed Web of Science ®Google Scholar
• Wylie B, Macri C, Mintern JD, et al. Dendritic cells and cancer: from biology to therapeutic intervention. Cancers (Basel). 2019 11;11(4):Apr.
   Web of Science ®Google Scholar
• Garg AD, Dudek AM, Agostinis P. Cancer immunogenicity, danger signals, and DAMPs: what, when, and how? Biofactors. 2013 Jul-Aug;39(4):355–367.
   PubMed Web of Science ®Google Scholar
• Worbs T, Hammerschmidt SI, Forster R. Dendritic cell migration in health and disease. Nat Rev Immunol. 2017 Jan;17(1):30–48.
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991 Jul 1;174(1):139–149.
   PubMed Web of Science ®Google Scholar
• Barbi J, Pardoll D, Pan F. Treg functional stability and its responsiveness to the microenvironment. Immunol Rev. 2014 May;259(1):115–139.
   PubMed Web of Science ®Google Scholar
• Sanin DE, Pearce EJ. The cell identity of cytotoxic T lymphocytes. Nat Immunol. 2016 Jan;17(1):45–46.
   PubMed Web of Science ®Google Scholar
• Sangiolo D, Martinuzzi E, Todorovic M, et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol. 2008 Jul;20(7):841–848.
   PubMed Web of Science ®Google Scholar
• Groh V, Rhinehart R, Secrist H, et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6879–6884.
   PubMed Web of Science ®Google Scholar
• Verneris MR, Karimi M, Baker J, et al. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 2004 Apr 15;103(8):3065–3072.
   PubMed Web of Science ®Google Scholar
• Lopez RD, Waller EK, Lu PH, et al. CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells. Cancer Immunol Immunother. 2001 Feb;49(12):629–640.
   PubMed Web of Science ®Google Scholar
• Schmeel LC, Schmeel FC, Coch C, et al. Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2015 May;141(5):839–849.
   PubMed Web of Science ®Google Scholar
• Marten A, Ziske C, Schottker B, et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother. 2001 Nov-Dec;24(6):502–510.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009 Jul 1;69(13):5383–5391.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao JX, Pan JH, et al. Adoptive immunotherapy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancer. PLoS One. 2014;9(11):e112662.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Qiao G, Wang X, et al. Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients’ preference-based study (PPPS). Clin Transl Oncol. 2019 Jun;21(6):721–728.
   PubMed Web of Science ®Google Scholar
• Xiao Z, Wang CQ, Zhou MH, et al. Clinical efficacy and safety of CIK plus radiotherapy for lung cancer: A meta-analysis of 16 randomized controlled trials. Int Immunopharmacol. 2018;61:363–375.
   PubMed Web of Science ®Google Scholar
• Lv S, Wang S, Qiao G, et al. Functional CD3(+)CD8(+)PD1(-) T cell accumulation and PD-L1 expression increases during tumor invasion in DCIS of the breast. Clin Breast Cancer. 2019 Oct;19(5):e617-e623.
   PubMed Web of Science ®Google Scholar
• Wang ZX, Cao JX, Wang M, et al. Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis. Cytotherapy. 2014 Jul;16(7):934–945.
   PubMed Web of Science ®Google Scholar
• Lin M, Liang S, Jiang F, et al. 2003-2013, a valuable study: autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer. Immunol Lett. 2017;183:37–43.
   PubMed Web of Science ®Google Scholar
• Hu J, Hu J, Liu X, et al. Effect and safety of cytokine-induced killer (CIK) cell immunotherapy in patients with breast cancer: A meta-analysis. Medicine (Baltimore). 2017 Oct;96(42):e8310.
   PubMed Web of Science ®Google Scholar
• Wang X, Ren J, Zhang J, et al. Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45). Clin Transl Oncol. 2016 Jan;18(1):82–87.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, T D, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018 May 10;4(5):e180013.
   PubMed Web of Science ®Google Scholar
• Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016 Jun;17(6):717–726.
   PubMed Web of Science ®Google Scholar
• De Rosa S, Sahnane N, Tibiletti MG, et al. EBV(+) and MSI gastric cancers harbor high PD-L1/PD-1 expression and high CD8(+) intratumoral lymphocytes. Cancers (Basel). 2018 Apr 1;10(4):pii: E102.
   PubMed Web of Science ®Google Scholar
• Kim KJ, Lee KS, Cho HJ, et al. Prognostic implications of tumor-infiltrating FoxP3+ regulatory T cells and CD8+ cytotoxic T cells in microsatellite-unstable gastric cancers. Hum Pathol. 2014 Feb;45(2):285–293.
   PubMed Web of Science ®Google Scholar
• Liu K, Song G, Hu X, et al. A positive role of cytokine-induced killer cell therapy on gastric cancer therapy in a Chinese population: a systematic meta-analysis. Med Sci Monit. 2015 Nov;4(21):3363–3370.
   Google Scholar
• Qiao G, Wang X, Zhou L, et al. Autologous dendritic cell-cytokine induced killer cell immunotherapy combined with S-1 plus cisplatin in patients with advanced gastric cancer: a prospective study. Clin Cancer Res. 2019 Mar 1;25(5):1494–1504.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhang X. Primary analysis for clinical efficacy of immunotherapy in patients with pancreatic cancer. Immunotherapy. 2016 Feb;8(2):223–234.
   PubMed Web of Science ®Google Scholar
• Jiang N, Qiao G, Wang X, et al. Dendritic cell/cytokine-induced killer cell immunotherapy combined with S-1 in patients with advanced pancreatic cancer: a prospective study. Clin Cancer Res. 2017 Sep 1;23(17):5066–5073.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24;389(10088):2492–2502.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018 Jul;19(7):940–952.
   PubMed Web of Science ®Google Scholar
• Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000 Sep 2;356(9232):802–807.
   PubMed Web of Science ®Google Scholar
• Cao J, Kong FH, Liu X, et al. Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis. World J Gastroenterol. 2019 Jul 21;25(27):3649–3663.
   PubMed Web of Science ®Google Scholar
• Wang X, Guo G, Guan H, et al. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. J Exp Clin Cancer Res. 2019 Feb 18;38(1):87.
   PubMed Web of Science ®Google Scholar
• Kong DS, Nam DH, Kang SH, et al. Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea. Oncotarget. 2017 Jan 24;8(4):7003–7013.
   PubMed Web of Science ®Google Scholar
• Wang ZX, Li JL, Cao JX, et al. Cytokine-induced killer cells in the treatment of patients with renal cell carcinoma: a pooled meta-analysis. Immunotherapy. 2014;6(6):787–795.
   PubMed Web of Science ®Google Scholar
• Zhao X, Zhang Z, Li H, et al. Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma. Cancer Lett. 2015 Jul 1;362(2):192–198.
   PubMed Web of Science ®Google Scholar
• Wolf B, Zimmermann S, Arber C, et al. Safety and tolerability of adoptive cell therapy in cancer. Drug Saf. 2019 Feb;42(2):315–334.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Bishop MR, Maloney DG, et al. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit ‘ALL’. Nat Rev Clin Oncol. 2018 Apr;15(4):218.
   PubMed Web of Science ®Google Scholar
• Qiao G, Wang X, Zhou X, et al. Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors. Int J Hyperthermia. 2019 Nov;36(sup1):74-82.
   Google Scholar
• Qiao G, Wang X, Zhou X, et al. Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors. Int J Hyperthermia. 2019 Nov;36(sup1):74–82.
   PubMedGoogle Scholar
• Chen CL, Pan QZ, Weng DS, et al. Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors. Oncoimmunology. 2018;7(4):e1417721.
   PubMed Web of Science ®Google Scholar